export default [
  {
    brandName: '',
    chemicalName: 'mrna-1273',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'mrna-based vaccine',
    numSites: '2',
    otherPartners: 'cepi',
    phase: '1',
    preferredName: 'mrna-1273',
    productId: 1,
    productType: '',
    repurposed: 'new',
    sponsors: 'moderna,national institute of allergy and infectious diseases',
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: 'nct04283461',
    siteLocations: [
      {
        name: 'Hospital Pkwy',
        city: 'San Jose',
        state: 'California',
        country: 'USA',
        lat: 37.239746,
        lon: -121.802344,
      },
      {
        name: 'Seoul Hospital',
        city: 'Seoul',
        state: '',
        country: 'South Korea',
        lat: 37.5665,
        lon: 126.978,
      },
    ],
  },
  {
    brandName: 'test',
    chemicalName: 'mrna-1272',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'treatment',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'mrna-based vaccine',
    numSites: '2',
    otherPartners: 'cepi',
    phase: '1',
    preferredName: 'mrna-1273',
    productId: 1,
    productType: '',
    repurposed: 'new',
    sponsors: 'moderna,national institute of allergy and infectious diseases',
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: 'nct04283461',
    siteLocations: [
      {
        name: 'Test',
        city: 'Test2',
        state: 'NY',
        country: 'USA',
        lat: 40.6643,
        lon: -73.9385,
      },
    ],
  },
]

export const ProdData = [
  {
    brand_name: '',
    chemical_name: 'mrna-1273',
    condition_or_disease: 'covid-19',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: 'mrna-based vaccine',
    num_sites: '2',
    other_partners: 'cepi',
    phase: '1',
    preferred_name: 'mrna-1273',
    product_id: 1,
    product_type: '',
    repurposed: 'new',
    site_locations:
      'kaiser permanente washington health research institute - seattle - washington,emory children\'s center - decatur - georgia',
    sponsors: 'moderna,national institute of allergy and infectious diseases',
    status: 'ongoing',
    therapeutic_approach: 'unknown',
    trial_id: 'nct04283461',
  },
  {
    brand_name: '',
    chemical_name: 'novavax vaccine',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'subunit vaccines',
    notes:
      'not totally clear that it is prophylactic vaccine. p1 expected late spring',
    num_sites: '',
    other_partners: 'cepi',
    phase: '',
    preferred_name: 'novavax vaccine',
    product_id: 2,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'novavax inc.,emergent biosolutions inc.',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'bnt162',
    condition_or_disease: '',
    countries: 'germany',
    country_codes: 'deu',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes:
      'expect clinical testing in late april. note this drug is also being developed in china with fosun pharma. assumed this is in discovery as no explicit statements aboit preclinical found',
    num_sites: '',
    other_partners: 'polymun',
    phase: '',
    preferred_name: 'bnt162',
    product_id: 3,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'pfizer inc.,biontech se',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'imperial college london vaccine',
    condition_or_disease: '',
    countries: 'united kingdon',
    country_codes: '',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: 'expect clinical testing in summer',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'imperial college london vaccine',
    product_id: 4,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'imperial college london',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: 'cellectra®',
    chemical_name: 'ino-4800',
    condition_or_disease: 'covid-19',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: '',
    num_sites: '',
    other_partners:
      'us dod,bill and melinda gates foundation,coalition for epidemic prepardness innovations funding',
    phase: '1',
    preferred_name: 'ino-4800',
    product_id: 5,
    product_type: '',
    repurposed: 'new',
    site_locations: 'united states',
    sponsors:
      'inovio pharmaceuticals inc.,beijing advaccine biotechnology.,us department of defense.,ology bioservices inc.',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: 'ad26 sars-cov-2',
    chemical_name: '',
    condition_or_disease: '',
    countries: 'belgium',
    country_codes: 'bel',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'gene therapies',
    notes: 'expect clinical testing no later than fall 2020',
    num_sites: '',
    other_partners: 'barda',
    phase: '',
    preferred_name: 'ad26 sars-cov-2',
    product_id: 6,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'janssen',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'sanofi vaccine',
    condition_or_disease: '',
    countries: 'france',
    country_codes: 'fra',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'subunit vaccines',
    notes:
      'they are repurposing vaccines that have been preclinically tested for sars - hence i have put the current status as preclinical',
    num_sites: '',
    other_partners: 'barda',
    phase: '',
    preferred_name: 'sanofi vaccine',
    product_id: 7,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'sanofi,barda',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: 'regeneron therapeutic',
    chemical_name: '',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      'plan to start human trials in summer 2020. technique was previously used to develop successful regn-eb3 ebola treatment.',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'regeneron therapeutic',
    product_id: 8,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'regeneron,hhs',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: 'vaxart vaccine',
    chemical_name: 'vaxart vaccine',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'subunit vaccines',
    notes:
      'oral tablet. recombinant vaccine. plan to initiate phase i trial in second half of 2020.',
    num_sites: '',
    other_partners: 'emergent',
    phase: '',
    preferred_name: 'vaxart vaccine',
    product_id: 9,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'vaxart',
    status: 'ongoing',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'university of queensland vaccine',
    condition_or_disease: '',
    countries: 'australia',
    country_codes: 'aus',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'subunit vaccines',
    notes: 'plans for clinical trials in july in queensland.',
    num_sites: '',
    other_partners:
      'cepi,the queensland government,paul ramsay foundation,a2 milk company',
    phase: '',
    preferred_name: 'university of queensland vaccine',
    product_id: 10,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'university of queensland',
    status: 'ongoing',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'vido-intervac vaccine candidate',
    condition_or_disease: '',
    countries: 'canada',
    country_codes: 'can',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'unknown',
    notes: '',
    num_sites: '',
    other_partners: 'canadian federal government',
    phase: '',
    preferred_name: 'vido-intervac vaccine candidate',
    product_id: 11,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'international vaccine centre,university of saskatchewan',
    status: 'ongoing',
    therapeutic_approach: 'unknown',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'chadox1 ncov-19',
    condition_or_disease: 'covid-19',
    countries: 'united kingdom',
    country_codes: 'gbr',
    current_status: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'subunit vaccines',
    notes: '',
    num_sites: '',
    other_partners: 'university of oxford',
    phase: '1',
    preferred_name: 'chadox1 ncov-19',
    product_id: 12,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'jenner institute,oxford vaccine group',
    status: 'ongoing',
    therapeutic_approach: 'unknown',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'niv pune vaccine candidate',
    condition_or_disease: '',
    countries: 'india',
    country_codes: 'ind',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'unknown',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'niv pune vaccine candidate',
    product_id: 13,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'national institute of virology-pune',
    status: 'ongoing',
    therapeutic_approach: 'unknown',
    trial_id: '',
  },
  {
    brand_name: 'university of hong kong vaccine',
    chemical_name: 'delns1-sars-cov2-rbd laiv',
    condition_or_disease: '',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'whole-pathogen vaccines',
    notes:
      'live-attenuated vaccine. plans for clinical trials in july. proof of concept testing done using mers-cov and various animal models.',
    num_sites: '',
    other_partners:
      'cepi,xiamen university,changchun-baike,hualan-bio,beijing wantai,sinovac,cnbg',
    phase: '',
    preferred_name: 'delns1-sars-cov2-rbd laiv',
    product_id: 15,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'university of hong kong',
    status: 'ongoing',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'ad5-ncov',
    condition_or_disease: 'covid 19',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'gene therapies',
    notes:
      'vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express sars-cov-2 spike protein; immunogenic action; current study is assessing evaluate the safety,reactogenicity and immunogenicity; active but not recruiting',
    num_sites: '1',
    other_partners:
      'institute of biotechnology-academy of military medical sciences-pla of china,jiangsu province centers for disease control and prevention,hubei provincial center for disease control and prevention,tongji hospital',
    phase: '1',
    preferred_name: 'ad5-ncov',
    product_id: 17,
    product_type: '',
    repurposed: 'new',
    site_locations:
      'hubei provincial center for disease control and prevention - wuhan - hubei china',
    sponsors: 'cansino biologics inc.',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'ino-4700',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'ino-4700',
    product_id: 19,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'inovio pharmaceuticals inc.,geneone life science',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'nasovax',
    chemical_name: 'nasovax analog (not currently specified)',
    condition_or_disease: 'covid-19',
    countries: 'united sates',
    country_codes: '',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes:
      'repurposing nasovax platform (recombinant intranasal delivery) for covid19 vaccine',
    num_sites: '',
    other_partners: 'altimmune',
    phase: '',
    preferred_name: 'nasovax analog (not currently specified)',
    product_id: 21,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: '',
    sponsors: 'altimmune',
    status: 'ongoing',
    therapeutic_approach: 'unknown',
    trial_id: '',
  },
  {
    brand_name: 'ibv',
    chemical_name:
      'avian coronavirus infectious bronchitis virus (ibv) vaccine',
    condition_or_disease: '',
    countries: 'israel',
    country_codes: 'isr',
    current_status: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'whole-pathogen vaccines',
    notes:
      'adaption of avian coronavirus infectious bronchitis virus vaccine for human use',
    num_sites: '',
    other_partners:
      'israel innovation authority,health ministry and the headquarters of the national digital israel initiative',
    phase: '',
    preferred_name:
      'avian coronavirus infectious bronchitis virus (ibv) vaccine',
    product_id: 22,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'migal research institute',
    status: 'ongoing',
    therapeutic_approach: 'unknown',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'tnx-1800',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'tnx-1800',
    product_id: 23,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'tonix pharmaceuticals',
    status: 'ongoing',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 's-trimer',
    chemical_name: 'recombinant subunit vaccine',
    condition_or_disease: '',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: '',
    num_sites: '',
    other_partners: 'glaxosmithkline',
    phase: '',
    preferred_name: 'recombinant subunit vaccine',
    product_id: 24,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'clover biopharmaceuticals',
    status: 'ongoing',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'linear dna vaccine',
    condition_or_disease: '',
    countries: 'united states,rome - italy',
    country_codes: '',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: 'pcr produced linear dna vaccine',
    num_sites: '',
    other_partners: 'applied dna sciences,takis biotech',
    phase: '',
    preferred_name: 'linear dna vaccine',
    product_id: 25,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'applied dna sciences,takis biotech',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: 'nanoflu',
    chemical_name: '',
    condition_or_disease: 'seasonal flu/influenza',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'manufacturing',
    indication: 'other',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'subunit vaccines',
    notes:
      'recombinant quadrivalent seasonal influenza vaccine using hemagglutinin (ha) protein nanoparticles',
    num_sites: '19',
    other_partners: 'novavax,emergent biosolutions inc,cepi',
    phase: '3',
    preferred_name: 'nanoflu',
    product_id: 26,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'novavax',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'leaps covid-19',
    condition_or_disease: 'covid-19',
    countries: 'usa',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'immunotherapy',
    num_sites: '',
    other_partners:
      'cel-sci,university of georgia’s (uga’s) center for vaccines',
    phase: '1',
    preferred_name: 'leaps covid-19',
    product_id: 52,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'cel-sci',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-broad spectrum',
    trial_id: '',
  },
  {
    brand_name: 'xofluza',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'roche-xofluza-187',
    product_id: 187,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'roche',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'plx cell product',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'pluristem-plx cell product-188',
    product_id: 188,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'pluristem',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'kaletra,aluvia',
    chemical_name: 'lopinavir,ritonavir',
    condition_or_disease: '2019-ncov',
    countries: 'multiple',
    country_codes: '',
    current_status: '?phase 4',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes:
      'unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. some studies are published: https://www.nejm.org/doi/pdf/10.1056/nejmoa2001282?articletools=true,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. note that for the highest study there were multiple phase 4 so i picked the largest one that had alrady started recruiting',
    num_sites: '1',
    other_partners: 'abbvie',
    phase: '4',
    preferred_name: 'lopinavir,ritonavir',
    product_id: 31,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'wuhan - china',
    sponsors: 'abbvie',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-antiretrovirals',
    trial_id: '',
  },
  {
    brand_name: 'kevzara',
    chemical_name: 'sarilumab',
    condition_or_disease: 'covid-19',
    countries: 'unites states',
    country_codes: '',
    current_status: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: '',
    num_sites: '57',
    other_partners: '',
    phase: '3',
    preferred_name: 'sarilumab',
    product_id: 32,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'if anyone else has done,copy accross',
    sponsors: 'regeneron,sanofi',
    status: 'ongoing',
    therapeutic_approach:
      'nonspecific anti-inflammatory and immunosuppressive drugs',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'hydroxychloroquine',
    condition_or_disease: 'covid 19',
    countries: 'na',
    country_codes: 'nam',
    current_status: '?phase 4',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: 'small molecule',
    notes: '',
    num_sites: 'not listed',
    other_partners: '',
    phase: '4',
    preferred_name: 'hydroxychloroquine',
    product_id: 33,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'not listed',
    sponsors:
      'numerous. university of minnesota,university of oxford,ihu-méditerranée infection and others,world health organization solidarity trial (chloroquine),new york state department of health (hydroxychloroquine with zithromax)',
    status: 'ongoing',
    therapeutic_approach: 'antimalarial drugs',
    trial_id: '',
  },
  {
    brand_name: 'tjm2',
    chemical_name: 'tj003234',
    condition_or_disease: '',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'phase 1',
    indication: 'ards',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      'antibody against gm-csf. previously passed a phase 1 trial. inds submitted for phase ii clinical trials in china usa and south korea.',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'tj003234',
    product_id: 35,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'i-mab biopharma',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'at-100',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      'recombinant surfactant protein developed to treat bronchopulmonary dysplatia. no timeline for clinical trials.',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'at-100',
    product_id: 36,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'airway therapeutics',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'tzls-501',
    condition_or_disease: '',
    countries: 'united kingdom',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: '',
    num_sites: '',
    other_partners: 'tiziana life sciences,novimmune',
    phase: '',
    preferred_name: 'tzls-501',
    product_id: 37,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'tiziana life sciences',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'oya1',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: '',
    num_sites: '',
    other_partners: 'oyagen',
    phase: '',
    preferred_name: 'oya1',
    product_id: 38,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'oyagen',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-broad spectrum',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'bpi-002',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes:
      'also being considered as a vaccine adjuvant to stimulate long term immunity,very little information is available on development stages - a patent has been filed for it by the company but it is not clear what that translates to,information in column t was seen on just one website',
    num_sites: '',
    other_partners: 'beyondspring inc',
    phase: '',
    preferred_name: 'bpi-002',
    product_id: 39,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'beyondspring inc',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-broad spectrum',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'np-120 (ifenprodil)',
    condition_or_disease: 'idiopathic pulmonary fibrosis',
    countries: 'canada',
    country_codes: 'can',
    current_status: 'phase 2',
    indication: 'ards',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      'therapeutic approach - receptor antagonist,drug originally evaluated for treatment of idiopathic pulmonary fibrosis',
    num_sites: '',
    other_partners: 'cascade chemistry',
    phase: '2',
    preferred_name: 'np-120 (ifenprodil)',
    product_id: 40,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'algernon pharmaceuticals',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'apn01',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'apn01',
    product_id: 41,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'university of british columbia,apeiron biologics',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'brilacidin',
    chemical_name: 'brilacidin tetrahydrochloride',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: '',
    num_sites: '',
    other_partners: 'innovation pharamaceuticals',
    phase: '',
    preferred_name: 'brilacidin tetrahydrochloride',
    product_id: 42,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'innovation pharmaceuticals',
    status: 'ongoing',
    therapeutic_approach: 'antibiotics and antiparasitics',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'leronlimab',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      'patient treatment underway via emergency ind,phase 2 trial protocol filed',
    num_sites: '',
    other_partners: 'redchip companies',
    phase: '',
    preferred_name: 'leronlimab',
    product_id: 43,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: '',
    sponsors: 'cytodyn',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: 'btx-025',
    chemical_name: 'novel viral inhibitor',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes:
      'novel galectin inhibitor for use in covid-19. currently pre-clinical.',
    num_sites: '',
    other_partners: 'bioxytran',
    phase: '',
    preferred_name: 'novel viral inhibitor',
    product_id: 44,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'bioxytran',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-not specified',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'actemra',
    condition_or_disease: 'severe covid-19 pneumonia',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      'first approved anti-il-6 receptor biologic available in both intravenous (iv) and subcutaneous (sc) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (ra).',
    num_sites: 'not disclosed',
    other_partners: 'roche',
    phase: '3',
    preferred_name: 'actemra',
    product_id: 45,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: 'global',
    sponsors: 'roche',
    status: 'ongoing',
    therapeutic_approach:
      'nonspecific anti-inflammatory and immunosuppressive drugs',
    trial_id: '',
  },
  {
    brand_name: 'galidesivir',
    chemical_name: 'bcx4430',
    condition_or_disease: 'yellow fever',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'phase 2',
    indication: 'other',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: 'neucleoside analogue for yellow fever,broad spectrum.',
    num_sites: 'not disclosed',
    other_partners: 'niaid,barda-nih',
    phase: '1',
    preferred_name: 'bcx4430',
    product_id: 46,
    product_type: '',
    repurposed: 'new',
    site_locations: 'not disclosed',
    sponsors: 'biocryst pharma',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-broad spectrum',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'regn3048-3051',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'regn3048-3051',
    product_id: 47,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'regeneron',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'sng001',
    condition_or_disease: 'covid-19',
    countries: 'united kingdom',
    country_codes: 'gbr',
    current_status: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'other',
    notes: 'inhaled forumation of beta-1a interferon',
    num_sites: '20',
    other_partners: 'public funding through shares',
    phase: '2',
    preferred_name: 'sng001',
    product_id: 48,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'uk',
    sponsors: 'synairgen research',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'amnioboost',
    condition_or_disease: 'covid-19',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'phase 1',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'other',
    notes: '',
    num_sites: '1',
    other_partners: 'lattice biologics',
    phase: '1',
    preferred_name: 'amnioboost',
    product_id: 49,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'seattle,usa',
    sponsors: 'lattice biologics',
    status: 'ongoing',
    therapeutic_approach: 'other',
    trial_id: '',
  },
  {
    brand_name: 'vaxart',
    chemical_name: 'vaast',
    condition_or_disease: 'covid-19',
    countries: 'usa',
    country_codes: 'usa',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'recombinant vaccines',
    notes:
      'oral vaccine,recombinant adenovirus expressing ha,non-replicating viral vector',
    num_sites: '',
    other_partners: 'emergent biosolutions,vaxart',
    phase: '1',
    preferred_name: 'vaast',
    product_id: 51,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'emergent biosolutions',
    status: 'ongoing',
    therapeutic_approach: 'other antiviral drugs',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'remdesivir',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'remdesivir',
    product_id: 56,
    product_type: '',
    repurposed: 'repurposed',
    site_locations: '',
    sponsors: 'columbia university',
    status: '',
    therapeutic_approach: 'antiviral- not specified',
    trial_id: '',
  },
  {
    brand_name: 'arbidol',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'pharmstandard-arbidol-186',
    product_id: 186,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'pharmstandard',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'tak-888',
    chemical_name: 'anti-sars-cov-2 polyclonal hyperimmune globulin (h-ig)',
    condition_or_disease: 'covid-19',
    countries: 'japan',
    country_codes: 'jpn',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'a plasma-derived therapy',
    num_sites: '',
    other_partners: 'takeda pharmaceutical company',
    phase: '1',
    preferred_name: 'anti-sars-cov-2 polyclonal hyperimmune globulin (h-ig)',
    product_id: 53,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'takeda pharmaceutical company',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-broad spectrum',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'azithromycin-hydroxychloroquine combination',
    condition_or_disease: '',
    countries: 'usa',
    country_codes: 'usa',
    current_status: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'other',
    notes: '',
    num_sites: '',
    other_partners: 'pfizer',
    phase: '',
    preferred_name: 'azithromycin-hydroxychloroquine combination',
    product_id: 54,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'pfizer',
    status: 'ongoing',
    therapeutic_approach: 'antibiotics and antiparasitics',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'ot-101',
    condition_or_disease: '',
    countries: 'united states',
    country_codes: 'usa',
    current_status: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein based',
    notes: 'used to treat covid-19 induced pneumonia',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'ot-101',
    product_id: 55,
    product_type: '',
    repurposed: 'repurposed',
    site_locations: '',
    sponsors: 'mateon therapeutics',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs- broad spectrum',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'modified anti-sars-cov-2 antibodies',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'prophylactic/therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes:
      '2 different modifications of one single clone of antibody originally developed against sars-cov-1,shown to act as both vaccine and therapeutic',
    num_sites: '',
    other_partners: 'wuxi biologics,biogen',
    phase: '',
    preferred_name: 'modified anti-sars-cov-2 antibodies',
    product_id: 59,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'vir biotechnology',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'sirna against  sars-cov-1/2',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: '350 candidates undergoing in vitro test',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'sirna against  sars-cov-1/2',
    product_id: 60,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'alnylam,vir biotechnology',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-antiretrovirals',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'sirna against  sars-cov-2',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'nucleic acid based therapies/vaccines',
    notes: '150 candidates under in vitro test',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'sirna against  sars-cov-2',
    product_id: 61,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'sirnaomics',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-antiretrovirals',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'bdb-001',
    condition_or_disease: 'covid-19',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'anti-c5a antibody,phase 2 trial number 2020l0003',
    num_sites: '',
    other_partners: 'staidson (beijing) biopharmaceuticals co. ltd,inflarx',
    phase: '2',
    preferred_name: 'bdb-001',
    product_id: 64,
    product_type: '',
    repurposed: 'repurposed-not approved',
    site_locations: '',
    sponsors: 'beijing defengrei biotechnology',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: 'sylvant',
    chemical_name: 'siltuximab',
    condition_or_disease: 'covid-19',
    countries: 'england',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'clinical trial nct04322188 started but phase unknown',
    num_sites: '1',
    other_partners: 'ergomed',
    phase: 'unknown',
    preferred_name: 'siltuximab',
    product_id: 65,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'papa giovanni xxiii hospital - italy',
    sponsors: 'eusa pharma',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: '47d11',
    condition_or_disease: '',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies',
    num_sites: '',
    other_partners: 'mount sinai,utrecht university,eurasmus mc',
    phase: '',
    preferred_name: '47d11',
    product_id: 66,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'harbour biomed',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'polytope mab therapy',
    condition_or_disease: '',
    countries: 'canada',
    country_codes: 'can',
    current_status: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'polytope mab therapy',
    product_id: 67,
    product_type: '',
    repurposed: 'new',
    site_locations: '',
    sponsors: 'immunoprecise antibodies ltd,evqlv',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'ifx-1',
    condition_or_disease: 'covid19',
    countries: 'germany',
    country_codes: 'deu',
    current_status: 'phase 1',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies',
    num_sites: '1',
    other_partners: '',
    phase: '1',
    preferred_name: 'ifx-1',
    product_id: 68,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'china',
    sponsors: 'inflarx',
    status: 'ongoing',
    therapeutic_approach: 'monoclonal antibodies',
    trial_id: '',
  },
  {
    brand_name: 'aplidin',
    chemical_name: 'plitidepsin',
    condition_or_disease: 'covid 19',
    countries: 'spain',
    country_codes: 'esp',
    current_status: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: 'anti-melanoma agent',
    num_sites: '',
    other_partners: 'csic',
    phase: '2',
    preferred_name: 'plitidepsin',
    product_id: 69,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: 'spanish hospitals',
    sponsors: 'pharmamar',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-immunosupressive',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'ganovo + ritonavir',
    condition_or_disease: 'covid19',
    countries: 'china',
    country_codes: 'chn',
    current_status: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: 'study patients discharged',
    num_sites: '',
    other_partners: 'shaoxing government',
    phase: '2',
    preferred_name: 'ganovo + ritonavir',
    product_id: 70,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations: '',
    sponsors: 'ascletis pharma',
    status: 'ongoing',
    therapeutic_approach: 'protease inhibitor',
    trial_id: '',
  },
  {
    brand_name: 'avigan,favilavir',
    chemical_name: 'favipiravir',
    condition_or_disease: 'covid-19',
    countries: 'japan',
    country_codes: 'jpn',
    current_status: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    molecule_type: 'small molecule',
    notes: 'japan has stockpile of 2 million.',
    num_sites: '11',
    other_partners: '',
    phase: 'not applicable',
    preferred_name: 'favipiravir',
    product_id: 72,
    product_type: '',
    repurposed: 'repurposed-approved',
    site_locations:
      'anhui medical university affiliated first hospital - hefei - china,guiqiang wang - beijing - china,peking university first hospital - beijing - china,cancer hospital union hospital tongji medical college huazhong university of science and technology - wuhan - china,ezhou central hospital - wuhan - china,huoshenshan hospital of wuhan - wuhan - china,jinyintan hospital of wuhan - wuhan - china,tongji hospital of huazhong university of science and technology - wuhan - china,west hospital union hospital huazhong university of science and technology - wuhan - china,wuhan pulmonary hospital - wuhan - china,zhongnan hospital of wuhan university - wuhan - china',
    sponsors: 'fujifilm,peking university first hospital',
    status: 'ongoing',
    therapeutic_approach: 'antiviral drugs-antiretrovirals',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'inactivated vaccine',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name:
      'beijing_institute_of_biological_products_wuhan_institute_of_biological_products-inactivated vaccine-75',
    product_id: 75,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors:
      'beijing institute of biological products,wuhan institute of biological products',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'sti-6991',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: 'vaccine - prophylactic',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'sorrento_therapeutics-sti-6991-102',
    product_id: 102,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'sorrento therapeutics',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'vtp-500',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'vaccitech-vtp-500-103',
    product_id: 103,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'vaccitech',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'nebulized ampion',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'ampio_pharmaceuticals-nebulized ampion-105',
    product_id: 105,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'ampio pharmaceuticals',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'piclidenoson',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'canfite_biopharma_ltd-piclidenoson-106',
    product_id: 106,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'can-fite biopharma ltd.',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'bdb-1',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'inflarx_nv-bdb-1-108',
    product_id: 108,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'inflarx n.v.',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'ryoncil',
    chemical_name: 'remestemcel-l',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'mesoblast_limited-remestemcel-l-109',
    product_id: 109,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'mesoblast limited',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'actemvra',
    chemical_name: 'tocilizumab',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'rogers_corporation-tocilizumab-110',
    product_id: 110,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'rogers corporation',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'diammonium',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'sino_biopharmaceuticals-diammonium-111',
    product_id: 111,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'sino biopharmaceuticals',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 't89',
    chemical_name: 'dantonic',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'tasly_pharmaceuticals-dantonic-112',
    product_id: 112,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'tasly pharmaceuticals',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'monoclonal antibodies',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'aztrazeneca_plc-monoclonal antibodies-113',
    product_id: 113,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'aztrazeneca plc',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'monoclonal antibodies',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'celtrion-monoclonal antibodies-114',
    product_id: 114,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'celtrion',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'monoclonal antibodies',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'dyadic_international-monoclonal antibodies-115',
    product_id: 115,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'dyadic international',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'mabvrilmumab',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'kiniksa_pharmaceuticals-mabvrilmumab-116',
    product_id: 116,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'kiniksa pharmaceuticals',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'plasma immunoglobulins',
    chemical_name: 'tak-888',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'takeda-tak-888-121',
    product_id: 121,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'takeda',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'plasma immunoglobulins',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'cers-plasma immunoglobulins-122',
    product_id: 122,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'cers',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'plasma immunoglobulins',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'grifols-plasma immunoglobulins-123',
    product_id: 123,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'grifols',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'plasma immunoglobulins',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'mount_sinai_health_system-plasma immunoglobulins-124',
    product_id: 124,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'mount sinai health system',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'plasma immunoglobulins',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'china_national_biotec-plasma immunoglobulins-125',
    product_id: 125,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'china national biotec',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'sti-4398',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'sorrento_therapeutics_inc-sti-4398-127',
    product_id: 127,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'sorrento therapeutics inc.',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'inopulse',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'bellepheron_therapeutics_inc-inopulse-129',
    product_id: 129,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'bellepheron therapeutics inc.',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'cytosorb',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'cytosorbents_corporation-cytosorb-130',
    product_id: 130,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'cytosorbents corporation',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'snx-5542',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'esanex-snx-5542-131',
    product_id: 131,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'esanex',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'mytesi',
    chemical_name: 'crofelemer',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'jaguar_health-crofelemer-132',
    product_id: 132,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'jaguar health',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: '',
    chemical_name: 'azvudine',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name: 'henan_provincial_peoples_hospital-azvudine-158',
    product_id: 158,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'henan provincial people\'s hospital',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
  {
    brand_name: 'sti-4920,cmab020',
    chemical_name: '',
    condition_or_disease: '',
    countries: '',
    country_codes: 'gbr',
    current_status: '',
    indication: '',
    interventionType: '',
    molecule_type: '',
    notes: '',
    num_sites: '',
    other_partners: '',
    phase: '',
    preferred_name:
      'sorrento_therapeutics_inc_mabpharm_limited-sti-4920,cmab020-179',
    product_id: 179,
    product_type: '',
    repurposed: '',
    site_locations: '',
    sponsors: 'sorrento therapeutics inc.,mabpharm limited',
    status: '',
    therapeutic_approach: '',
    trial_id: '',
  },
]
